An agent-based modeling framework linking inflammation and cancer using evolutionary principles: Description of a generative hierarchy for the hallmarks of cancer and developing a bridge between mechanism and epidemiological data

Mathematical Biosciences

Volumn 260, Issue , 2015, Pages 16-24

  An, Gary ^a   Kulkarni, Swati ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Agent based modeling; Cancer; Computational biology; Evolution; Inflammation; Systems biology

Indexed keywords

AUTONOMOUS AGENTS; COMPUTATIONAL METHODS; DIGITAL STORAGE; DISEASES; PATHOLOGY; SIMULATION PLATFORM;

AGENT-BASED MODEL; CANCER; COMPUTATIONAL BIOLOGY; EVOLUTION; INFLAMMATION; SYSTEMS BIOLOGY;

BIOLOGY;

ARTICLE; BIOLOGICAL MODEL; CANCER GROWTH; CARCINOGENESIS; EPIDEMIOLOGICAL DATA; GENETIC STABILITY; GENOME; HUMAN; INFLAMMATION; INFLAMMATION AND CANCER AGENT BASED MODEL; MALIGNANT NEOPLASTIC DISEASE; MUTAGENICITY; PREMENOPAUSE; SIMULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; AFRICAN AMERICAN; BREAST TUMOR; COMPLICATION; ETHNOLOGY; EVOLUTION; FEMALE; IMMUNOLOGY; NEOPLASMS; SYSTEMS BIOLOGY;

EUKARYOTA; PROKARYOTA;

AFRICAN AMERICANS; BIOLOGICAL EVOLUTION; BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; HUMANS; INFLAMMATION; NEOPLASMS; PREMENOPAUSE; SYSTEMS BIOLOGY;

EID: 84921433780     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2014.07.009     Document Type: Article

References (41)

1. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 2012, 30:677-706.
2. Elinav E., et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13(11):759-771.
3. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
4. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010, 20(1):65-71.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
6. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012, 13(5):518-527.
7. Rothwell P.M., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379(9826):1602-1612.
8. Colotta F., et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
9. Zitvogel L., et al. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 2008, 118(6):1991-2001.
10. Nathan C. Points of control in inflammation. Nature 2002, 420(6917):846-852.
11. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140(6):871-882.
12. Vodovotz Y., et al. Translational systems biology of inflammation. PLoS Comput. Biol. 2008, 4(4):e1000014.
13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
14. Hunt C.A., et al. At the biological modeling and simulation frontier. Pharm. Res. 2009.
15. Wilensky U. NetLogo. Center for Connected Learning 1999, Northwestern University, Evanston, IL,
16. Chapa J., et al. Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS ONE 2013, 8(5):e64091.
17. An G. Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 2001, 16(4):266-273.
18. An G. In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling. Crit. Care Med. 2004, 32(10):2050-2060.
19. An G. Introduction of an agent-based multi-scale modular architecture for dynamic knowledge representation of acute inflammation. Theor. Biol. Med. Model 2008, 5(1):11.
20. Csete M.E., Doyle J.C. Reverse engineering of biological complexity. Science 2002, 295(5560):1664-1669.
21. Doyle J., Csete M. Motifs, control, and stability. PLoS Biol. 2005, 3(11):e392.
22. Doyle J.C., Csete M. Architecture, constraints, and behavior. Proc. Natl. Acad. Sci. USA 2011, 108(Suppl 3):15624-15630.
23. M. Eden, Proceedings of the 4th Berkely Symposium on Mathematics and Probability, in: 4th Berkeley Symposium on Mathematics and Probability, University of California Press, Berkeley, CA, 1961.
24. Institute, N.C. Cancer Intervention and Surveillance Modeling Network: Breast Cancer Modeling. (cited 30.04.14). http://cisnet.cancer.gov/breast/profiles.html.
25. Hunt C.A., et al. Physiologically based synthetic models of hepatic disposition. J. Pharmacokinet Pharmacodyn. 2006, 33(6):737-772.
26. Kim S.H., et al. A computational approach to resolve cell level contributions to early glandular epithelial cancer progression. BMC Syst. Biol. 2009, 3:122.
27. Engelberg J.A., et al. MDCK cystogenesis driven by cell stabilization within computational analogues. PLoS Comput. Biol. 2011, 7(4):e1002030.
28. Engelberg J.A., Ropella G.E., Hunt C.A. Essential operating principles for tumor spheroid growth. BMC Syst. Biol. 2008, 2:110.
29. Wilkie K.P., Hahnfeldt P. Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy. Cancer Res. 2013, 73(12):3534-3544.
30. Wilkie K.P., Hahnfeldt P. Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. Interface Focus 2013, 3(4):20130010.
31. Enderling H., Hlatky L., Hahnfeldt P. Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor. Biol. Med. Model 2012, 9:31.
32. Hillen T., Enderling H., Hahnfeldt P. The tumor growth paradox and immune system-mediated selection for cancer stem cells. Bull. Math. Biol. 2013, 75(1):161-184.
33. Sherratt J.A., Nowak M.A. Oncogenes, anti-oncogenes and the immune response to cancer: a mathematical model. Proc. Biol. Sci. 1992, 248(1323):261-271.
34. Ledzewicz U., Olumoye O., Schattler H. On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth. Math Biosci. Eng. 2013, 10(3):787-802.
35. Castiglione F., Piccoli B. Cancer immunotherapy, mathematical modeling and optimal control. J. Theor. Biol. 2007, 247(4):723-732.
36. Al-Tameemi M., Chaplain M., d'Onofrio A. Evasion of tumours from the control of the immune system: consequences of brief encounters. Biol. Direct 2012, 7:31.
37. Robertson-Tessi M., El-Kareh A., Goriely A. A mathematical model of tumor-immune interactions. J. Theor. Biol. 2012, 294:56-73.
38. Bru A., et al. The universal dynamics of tumor growth. Biophys. J. 2003, 85(5):2948-2961.
39. Carey L.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
40. Stead L.A., et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009, 11(2):R18.
41. Reiner A.P., et al. Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. Am. J. Hum. Genet. 2012, 91(3):502-512.